A Study of DM005 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit. Participants with advanced solid malignant tumors will be treated with DM005 on Day 1 of each cycle (every

Trial Details

NCT ID
NCT06515990
Phase
PHASE1
Sponsor
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • DM005
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Dallas, Texas, United States|32.78306,-96.80667
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • North Ryde, New South Wales, Australia|-33.79677,151.12436

Key Eligibility Criteria

  • Common inclusion criteria for both Parts
  • Participants must have the ability to understand and willingness to sign a written informed consent document.
  • Participants who have pathologically or cytologically documented metastatic/advanced NSCLC, gastroesophageal cancer, CRC, HCC, pancreatic cancer, o…
  • Participants must be ≥18 years of age on the day of signing the informed consent form (ICF).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →